Advertisement

Discussion on the indication of allogeneic stem cell transplantation for advanced cutaneous T cell lymphomas

  • Silvana NovelliEmail author
  • Anna Monter
  • M. Pilar García-Muret
  • Rodrigo Martino
  • Javier Briones
  • Jorge Sierra
Review Article

Abstract

Advanced cutaneous T cell lymphoma (CTCL) patients have a dismal prognosis, especially those relapsing or progressing after systemic therapy. No curative therapies are available, but some new agents have prolonged disease-free survival time with a good toxicity profile. Allogeneic stem cell transplantation (allo-SCT) offers the longest disease-free survival, potentially representing the best therapeutic option for eligible patients. In the present article, we discuss current evidence about allo-SCT for CTCL patients, timing, and new therapeutic options before allo-SCT, taking into account some considerations that may impact clinical outcome.

Keywords

Cutaneous T cell lymphoma Mycosis fungoide Sézary syndrome Allogeneic hematopoietic transplantation 

Notes

Acknowledgements

This work was supported in part by Grant 2017 SGR 1395 from the Catalan Government, Grant from “Obra Social La Caixa” Barcelona Spain, and grant Tercel RD16/0011/0028 from the Instituto de Salud Carlos III, Ministerio de Economía y Competitividad, Spain.

Compliance with ethical standard

Conflict of interest

The authors report no conflicts of interest.

References

  1. 1.
    Song SX, Willemze R, Swerdlow SH, Kinney MC, Said JW. Mycosis fungoides. Am J Clin Pathol. 2013;139(4):466–90 (Internet).CrossRefGoogle Scholar
  2. 2.
    Olsen E, Vonderheid E, Pimpinelli N. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713–23.CrossRefGoogle Scholar
  3. 3.
    Wilcox RA. Cutaneous T cell lymphoma: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol. 2011;86(11):928–48.CrossRefGoogle Scholar
  4. 4.
    Kim Y. Long-term outcome of 525 Patients with mycosis fungoides and sézary syndrome. Arch Dermatol. 2003;139:857–66.Google Scholar
  5. 5.
    Sureda A, Bader P, Cesaro S, Dreger P, Duarte RF, Dufour C, et al. Indications for allo- and auto-SCT for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2015. Bone Marrow Transpl. 2015;50(8):1037–56.CrossRefGoogle Scholar
  6. 6.
    Agar NS, Wedgeworth E, Crichton S, Mitchell TJ, Cox M, Ferreira S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–9.CrossRefGoogle Scholar
  7. 7.
    Willemze R, Dreyling M. Primary cutaneous lymphomas: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):630–40.Google Scholar
  8. 8.
    Ingen-Housz-Oro S, Bachelez H, Verola O, Lebbé C, Marolleau JP, Hennequin C, et al. High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma. Bone Marrow Transpl. 2004;33(6):629–34.CrossRefGoogle Scholar
  9. 9.
    Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, et al. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015;26(12):2490–5.Google Scholar
  10. 10.
    Duarte RF, Canals C, Onida F, Gabriel IH, Arranz R, Arcese W, et al. Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol. 2010;28(29):4492–9.CrossRefGoogle Scholar
  11. 11.
    Sorror ML, Maris MB, Storb R, Baron F, Sandmaier BM, Maloney DG, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912–9.CrossRefGoogle Scholar
  12. 12.
    Arulogun SO, Prince HM, Ng J, Lade S, Ryan GF, Blewitt O, et al. Long-term outcomes of patients with advanced-stage cutaneous T cell lymphoma and large cell transformation. Blood. 2008;112(8):1–3.CrossRefGoogle Scholar
  13. 13.
    Herrmann JL, Hughey LC. Recognizing large-cell transformation of mycosis fungoides. J Am Acad Dermatol. 2012;67(4):665–72.CrossRefGoogle Scholar
  14. 14.
    Benner MF, Jansen PM, Vermeer MH, Willemze R. Prognostic factors in transformed mycosis fungoides: a retrospective analysis of 100 cases. Blood. 2012;119(7):1643–9.CrossRefGoogle Scholar
  15. 15.
    Diamandidou E, Colome-Grimmer M, Fayad L, Duvic M, Kurzrock R. Transformation of mycosis fungoides/sezary syndrome: clinical characteristics and prognosis. Blood. 1998;92(4):1150–9.Google Scholar
  16. 16.
    Vergier B, de Muret A, Beylot-Barry M, Vaillant L, Ekouevi D, Chene G, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French study group of cutaneious lymphomas. Blood. 2000;95(7):2212–8.Google Scholar
  17. 17.
    Hughes CFM, Khot A, Mccormack C, Lade S, Westerman DA, Twigger R, et al. Lack of durable disease control with chemotherapy for mycosis fungoides and Sézary syndrome: a comparative study of systemic therapy. Blood. 2015;125(1):71–82.CrossRefGoogle Scholar
  18. 18.
    European Medicines Agency–EMA. Annex I summary of product characteristics–ADCETRIS. 2018;1–47. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002455/WC500135055.pdf. Accessed 27 Oct 2018.
  19. 19.
    Horwitz SM, Scarisbrick JJ, Dummer R, Duvic M, Kim YH, Walewski J, et al. Updated analyses of the international, open-label, randomized, phase 3 alcanza study: longer-term evidence for superiority of brentuximab vedotin versus methotrexate or bexarotene for CD30-positive cutaneous T cell lymphoma (CTCL). Blood. 2017;130(Suppl 1):1509.Google Scholar
  20. 20.
    Novelli S, García-Muret P, Sierra J, Briones J. Alemtuzumab treatment for Sézary syndrome: a single-center experience. J Dermatol Treat. 2016;27(2):179–81.CrossRefGoogle Scholar
  21. 21.
    Bernengo MG, Quaglino P, Comessatti A, Ortoncelli M, Novelli M, Lisa F, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007;92(6):784–94.CrossRefGoogle Scholar
  22. 22.
    European Medicines Agency–EMA. Annex I summary of product characteristics–POTELIGEO. 2018; p 1. https://www.ema.europa.eu/documents/smop-initial/chmp-summary-positive-opinion-poteligeo_en.pdf. Accessed 27 Oct 2018.
  23. 23.
    Kondo T, Takiguchi M. Human memory CCR23 + CD8 + T cell subset has the ability to produce multiple cytokines. Int Immunol. 2009;21(5):523–32.CrossRefGoogle Scholar
  24. 24.
    Hoffmann P, Ermann J, Edinger M, Fathman CG, Strober S. Donor-type CD4+ CD25+ regulatory T Cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med. 2002;196(3):389–99.CrossRefGoogle Scholar
  25. 25.
    Inoue Y, Fuji S, Tanosaki R, Fukuda T. Pretransplant mogamulizumab against ATLL might increase the risk of acute GVHD and non-relapse mortality. Bone Marrow Transpl. 2016;51(5):725–7.CrossRefGoogle Scholar
  26. 26.
    Kawano N, Kuriyama T, Yoshida S, Kawano S, Yamano Y, Marutsuka K, et al. The impact of a humanized CCR26 antibody (Mogamulizumab) on patients with aggressive-type adult T cell leukemia-lymphoma treated with allogeneic hematopoietic stem cell transplantation. J Clin Exp Hematop. 2017;56(3):135–44.CrossRefGoogle Scholar
  27. 27.
    Le Bourgeois A, Labopin M, Blaise D, Ceballos P, Vigouroux S, de Latour R Peffault, et al. Reduced-intensity versus reduced-toxicity myeloablative fludarabine/busulfan-based conditioning regimens for allografted non-Hodgkin lymphoma adult patients: a retrospective study on behalf of the Société Francophone de Greffe de Moelle et de Thérapie Cellulaire. Ann Oncol. 2017;28(9):2191–8.CrossRefGoogle Scholar
  28. 28.
    Schlaak M, Kurschat P, Shimabukuro-Vornhagen A, Scheid C, Chemnitz J, Stadler R, et al. Donor lymphocyte infusions combined with systemic PUVA/bexarotene as an effective bimodal immunologic approach in a patient with relapsed cutaneous T cell lymphoma after allogeneic stem cell transplantation. Transpl Immunol. 2011;25(2–3):163–6.CrossRefGoogle Scholar
  29. 29.
    Montoro J, Sanz J, Sanz GF, Sanz MA. Advances in haploidentical stem cell transplantation for hematologic malignancies. Leuk Lymphoma. 2016;57(8):1766–75.CrossRefGoogle Scholar
  30. 30.
    Mariotti J, Devillier R, Bramanti S, Sarina B, Furst S, Granata A, et al. T Cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with Hla-identical rela. Biol Blood Marrow Transpl. 2018;24(3):627–32.CrossRefGoogle Scholar
  31. 31.
    Kanate AS, Mussetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, et al. Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. Blood. 2016;127(7):938–47.CrossRefGoogle Scholar
  32. 32.
    Luznik L, O’Donnell PV, Fuchs EJ. Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39(6):683–93.CrossRefGoogle Scholar
  33. 33.
    Ijaz A, Khan AY, Malik SU, Faridi W, Fraz MA, Usman M, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transpl. 2019;25(1):94–9.CrossRefGoogle Scholar
  34. 34.
    Oshima Y, Tanimoto T, Yuji K, Tojo A. Association between GvHD and nivolumab in the FDA adverse event reporting system. Bone Marrow Transpl. 2017;52(10):1463–4.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  1. 1.Hematology DepartmentHospital de la Santa Creu i Sant Pau, José Carreras Leukemia Research Institute and IIB Sant Pau, Universitat Autònoma de BarcelonaBarcelonaSpain
  2. 2.Dermatology DepartmentHospital de la Santa Creu i Sant PauBarcelonaSpain

Personalised recommendations